Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
M-CENK + N-803
- Development stage
- Unknown
- Lead developer
- ImmunityBio
- Modality
- Adoptive Cell Transfer → Cell Therapies, Cytokines & Interferons → Recombinant Proteins and Enzymes
- Administration
- Intravenous, Subcutaneous
01
Overview
**M-CENK + N-803** is an investigational combination therapy consisting of two key components: M-CENK, an autologous adoptive cell therapy using expanded and activated natural killer (NK) cells, and N-803, a recombinant IL-15 superagonist complex (also known as nogapendekin alfa inbakicept). M-CENK is produced from a patient's own peripheral blood mononuclear cells (PBMCs) and is designed to directly mediate cytotoxic effects on tumor cells. N-803 acts by stimulating proliferation and activation of NK cells and CD8+ T cells, thereby enhancing innate and adaptive antitumor immune responses. The combination is under investigation primarily for the treatment of platinum-resistant high-grade ovarian cancer, with clinical trials evaluating safety and efficacy in this population.
- Brand names
- Anktiva
- Other names
- nogapendekin alfa inbakicept
02
Targets
IL-15R (Interleukin 15 receptor alpha/interleukin 15 complex)
Beyond the preview
Go deeper on M-CENK + N-803.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on M-CENK + N-803.